In the ever-evolving landscape of pharmaceutical marketing, the industry faces a delicate balance between informing the public and adhering to strict regulations. This challenge was thrust into the spotlight with the recent case of CSL Seqirus and the alleged promotion of their prescription-only Flucelvax Influenza vaccine on the social media platform LinkedIn.
![Navigating the New Frontier: The First Abridged Complaint under the 2024 ABPI Code](https://darkdrug.com/wp-content/uploads/2025/01/AdobeStock_979828428-scaled-e1737135181902-1080x675.jpeg)